Navigation Links
University of Minnesota startup to treat challenging bacterial infection

A live biological preparation developed by University of Minnesota researchers could put a stop to an increasingly prevalent, and sometimes deadly, infection caused by the bacterium Clostridium difficile. CIPAC Limited, based in Australia with subsidiaries in California, will continue to work with the university to advance the technology to treat patients by using frozen and, eventually, encapsulated preparations.

C. difficile affects several million people and is linked to 14,000 deaths per year in the United States, according to the Centers for Disease Control and Prevention. Symptoms of C. difficile infection include fever, nausea, and diarrhea, and most often occur following a prescribed course of antibiotics. The antibiotics kill normal microbes that live in the colon, thereby making the patient more susceptible to infections such as C. difficile.

Paradoxically, while the cause of C. difficile infection is exposure to antibiotics, the infection itself is also treated using antibiotics, which can make things worse. C. difficile infections typically affect older adults in hospitals or in long-term care facilities, but is increasingly spreading into the wider community. In recent years it has become more frequent, more severe and more difficult to treat. Patients suffering from the infection require costly care -- researchers suggest it costs $2,500-7,000 to treat each patient suffering from C. difficile.(1)

"C. difficile can be suppressed with antibiotics, which have the unfortunate side effect of killing off the normal colon bacteria that offer protection against infection," says Alexander Khoruts, M.D., co-inventor and associate professor of medicine within the university's division of Gastroenterology, Hepatology and Nutrition.

"Antibiotics don't work very well because they only suppress the C. difficile. Once you remove the antibiotic, it produces more of the infection," says Michael Sadowsky, co-inventor and McKnight University professor in the Biotechnology Institute and department of Soil, Water, and Climate.

The invention, a bacterial preparation, can enable restoration of normal bacteria in the colon.

"We are very excited to be working with the University of Minnesota in commercializing a treatment that has approximately 95% efficacy," says Geoff Rosenhain, founder of CIPAC. "Our goal is to bring to market a safe, natural and effective alternative to current treatment options, and to restore the wellbeing of patients suffering from debilitating C. difficile infections."

CIPAC is working with the FDA to begin clinical trials for the preparation. The technology was licensed exclusively to CIPAC by the university's Office for Technology Commercialization.


Contact: John Merritt
University of Minnesota

Related medicine news :

1. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
2. University of Houston Graduate College of Social Work announces partnership with MD Anderson
3. Neuropsychologist receives University of Houstons highest faculty honor
4. Louisiana Tech University professor earns NSF Early Career Development grant
5. Rice University student engineers automate limb lengthening for kids
6. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
7. University of Cincinnati researchers win $3.7M grant from US Department of Defense
8. Oxford University Press partners with the Physical Society of Japan
9. Fewer women need repeat breast cancer surgeries with new service at University of Michigan
10. Kessler Foundation scientist addresses opening of science complex of William Paterson University
11. 90 percent of firefighters exhibit symptoms of PTSD according to Ben-Gurion University researchers
Post Your Comments:
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... RoamRight, a ... up with Public Television’s Travel With Kids to promote family vacations ... Simmons family as they explore international destinations and educate families about the people and ...
(Date:11/30/2015)... ... November 30, 2015 , ... A novel class of ... be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant ... that small molecule analogs that target the functions of SecA, a central part ...
(Date:11/30/2015)... Plains, NJ (PRWEB) , ... November 30, 2015 , ... ... in a comfortable and convenient setting. , When you have dental problems, you need ... the field and can effectively diagnose and treat your needs, a friendly dentist who ...
(Date:11/30/2015)... ... ... Using a combination of two blood sugar tests rather than a single test ... study by researchers at the School of Public Health at Georgia State University. , ... Glucose Tests ,” published in Frontiers in Public Health, the researchers noted that 24 ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... general dentistry out of Glen Ridge, NJ. He has both advanced training ... optimal mastication. He is also an expert in cosmetic dentistry. He is ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , 1 décembre 2015 ... exposition et conférence d,Asie portant sur ... sur l,industrie manufacturière, se tiendra à ... 20 au 22 avril 2016. ... Photo - ...
(Date:11/30/2015)... , December 1, 2015 ... adds "Endometriosis - Pipeline Review, H2 ... overview on therapeutic pipeline of Endometriosis and ... effective counter strategies to gain competitive advantage. ... targets and MOAs to produce first-in-class and ...
(Date:11/30/2015)... CUPERTINO, Calif. , Nov. 30, 2015 ... announced today that Matt Hogan , ... the Oppenheimer Healthcare Conference on Tuesday, December ... conference is being held at the Westin ... will also be available for one-on-one meetings ...
Breaking Medicine Technology: